跳至主要内容
临床试验/EUCTR2017-000250-19-ES
EUCTR2017-000250-19-ES进行中(未招募)1 期

Effect of calcium dobesilate in early stages of diabetic retinopathy - CADODIAME

Fundació Hospital Universitari Vall d'Hebron - Institut de Recersa (VHIR)0 个研究点目标入组 60 人开始时间: 2017年4月7日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients with type 2 diabetes mellitus.
  • Subclinical diabetic macular edema.
  • ETDRS score 20-47.
  • Duration of diabetes = 5 years.
  • Age between 45 and 70 years (both included)
  • HbA1c =7% and =8.5% in the previous 6 months and at screening.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 60
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Medical record of laser photocoagulation.
  • Presence of any retinal disease other than diabetic retinopathy.
  • Patients with a refractive error of =5 diopters in one of the two eyes.
  • Pupillary dilation or any eye defect that does not allow good quality images of fundus.
  • Medical record of ocular surgery in the 6 months prior to randomization.
  • Advanced chronic kidney disease (= stage 4).
  • known Allergy or intolerance ti IMP
  • Pregnancy or child-bearing age women that don't accept or can't use anticonceptive methodes during all the study
  • Patients that cannot follow the study indications
  • Use of an IMP within the last 30 days prior to screening visit

研究者

发起方
Fundació Hospital Universitari Vall d'Hebron - Institut de Recersa (VHIR)

相似试验

Effect of calcium dobesilate in early stages of... | 临床试验